| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)NCT04816604 | Gossamer Bio USA, Inc. | Phase 2 | Terminated | 2026-09-09Actual |
| A Study to Evaluate EDP 938 Regimens in Children With RSVNCT04816721 | ENTA | Phase 2 | Completed | 2024-08-19Actual |
| BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid TumorsNCT04819373 | Eikon Therapeutics | Phase 2 | Completed | 2023-04-01Actual |
| Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I DisorderNCT04819776 | Vanda Pharmaceuticals | Phase 3 | Completed | 2022-09-07Actual |
| A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B InfectionNCT04820686 | Assembly Biosciences | Phase 2 | Terminated | 2023-03-30Actual |
| ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)NCT04831281 | LeonaBio | Phase 2 | Terminated | 2023-04-19Actual |
| Study of ARO-ANG3 in Adults With Mixed DyslipidemiaNCT04832971 | Arrowhead Pharmaceuticals | Phase 2 | Completed | 2022-08-30Actual |
| A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection FractionNCT04836182 | IONS | Phase 2 | Completed | 2022-10-19Actual |
| VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on StudyNCT04842747 | VERU | Phase 3 | Completed | 2022-07-06Actual |
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentNCT04844749 | VERU | Phase 3 | Terminated | 2023-05-04Actual |
| Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in AdultsNCT04845178 | AEON | Phase 2 | Completed | 2024-06-19Actual |
| Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)NCT04845620 | ARQT | Phase 3 | Completed | 2023-06-01Actual |
| A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.NCT04847544 | ALDX | Phase 2 | Completed | 2021-10-15Actual |
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMNCT04848506 | Cytokinetics | Phase 2, Phase 3 | Enrolling by invitation | 2029-03Estimated |
| A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)NCT04849741 | IONS | Phase 3 | Active not recruiting | 2025-08-22Actual |
| A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical DystoniaNCT04849988 | AEON | Phase 2 | Completed | 2022-07-11Actual |
| Study of SAB-176 in Healthy Adult ParticipantsNCT04850898 | SABS | Phase 2 | Completed | 2021-10-08Actual |
| A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsNCT04854434 | KPTI | Phase 2 | Terminated | 2022-06-24Actual |
| Safety of REL-1017 for Major Depressive DisorderNCT04855760 | RLMD | Phase 3 | Completed | 2023-07-27Actual |
| Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionNCT04856085 | VIR | Phase 2 | Completed | 2026-03-16Actual |
| A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne VulgarisNCT04856917 | Vanda Pharmaceuticals | Phase 2 | Completed | 2022-02-01Actual |
| A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis SuppurativaNCT04856930 | Vanda Pharmaceuticals | Phase 2 | Completed | 2022-07-15Actual |
| Evaluation of ADG20 for the Prevention of COVID-19NCT04859517 | IVVD | Phase 2, Phase 3 | Terminated | 2022-11-04Actual |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943 | VERU | Phase 3 | Terminated | 2024-01-09Actual |
| A Study of AL102 in Patients With Progressing Desmoid TumorsNCT04871282 | IMNM | Phase 2, Phase 3 | Active not recruiting | 2025-12-03Actual |
| Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical DystoniaNCT04871451 | AEON | Phase 2 | Completed | 2023-07-24Actual |
| A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and SarcopeniaNCT04874350 | LPCN | Phase 2 | Completed | 2023-12-18Actual |
| A Trial to Investigate Recovery From COVID-19 With C21 in Adult SubjectsNCT04880642 | Vicore Pharma AB | Phase 3 | Completed | 2022-04-25Actual |
| A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson DiseaseNCT04884815 | RARE | Phase 1, Phase 2 | Active not recruiting | 2029-03Estimated |
| Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseNCT04886063 | LeonaBio | Phase 2, Phase 3 | Terminated | 2024-10-23Actual |
Trial details
- Registry ID
- NCT04816604
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04816721
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04819373
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04819776
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04820686
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04831281
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04832971
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04836182
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04842747
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04844749
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04845178
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04845620
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04847544
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04848506
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04849741
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04849988
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04850898
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04854434
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04855760
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04856085
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04856917
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04856930
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04859517
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04869943
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04871282
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04871451
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04874350
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04880642
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04884815
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT04886063
- Phase
- Phase 2, Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.